***Additional I-SPOT Criteria include:***

**Inclusion**

1. Able to provide a valid informed consent to be in the study (self or their legally accepted representative)

**Exclusion**

**a.** Current or anticipated use of systemic anticoagulants

**b.** Known moderate or severe hepatic insufficiency (as defined by INR>1.5 if known or history of variceal bleeding or hepatic encephalopathy)

**c.** Prior or concurrent thrombotic or hypercoagulable condition (Antiphospholipid antibody syndrome; Antithrombin III, Protein C or S deficiencies; Congenital or Inherited Factor deficiencies; Sickle cell disease)